A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of SAR440340, in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Latest Information Update: 24 Nov 2022
At a glance
- Drugs Itepekimab (Primary) ; Corticosteroids
- Indications Chronic obstructive pulmonary disease
- Focus Proof of concept; Therapeutic Use
- Sponsors Sanofi
- 27 Feb 2020 Status changed from active, no longer recruiting to completed.
- 01 Nov 2019 Planned number of patients changed from 340 to 850.
- 12 Sep 2019 Planned primary completion date changed from 1 Dec 2019 to 2 Oct 2019.